Review Update: $ACU (stay away)
- I first reviewed this stock on March 1, 2022.
- I now have a NEGATIVE outlook on the stock, after their Q1 financial report was released.
- If I owned this stock, I would’ve sold immediately after seeing their report.
- Their 2022 net income/EPS are NOT on track to beat 2021.
Q1 21’: $43.5M
Q1 22’: $43.3M
Q1 21’: $2.1M
Q1 22’: $830K
EARNINGS PER SHARE (EPS):
Q1 21’: 0.61
Q1 22’: 0.24
FOLLOW ME 😎
To hear about high-potential stocks EARLY, long before they produce life-changing returns. (and to know which stocks to stay away from)